Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO - Free Report) had its target price trimmed by Stifel Nicolaus from $17.00 to $15.00 in a report released on Thursday morning,Benzinga reports. They currently have a hold rating on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a "buy" rating and set a $23.00 target price on shares of Bausch + Lomb in a report on Tuesday, February 18th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $15.00 price objective (down previously from $24.00) on shares of Bausch + Lomb in a research note on Friday, March 28th. Bank of America decreased their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research report on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, February 20th. Finally, Citigroup cut Bausch + Lomb from a "buy" rating to a "neutral" rating and cut their price target for the company from $24.00 to $22.00 in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $18.82.

Remove Ads

Bausch + Lomb Stock Performance

Shares of NYSE BLCO traded down $0.46 during mid-day trading on Thursday, reaching $11.41. 201,111 shares of the company were exchanged, compared to its average volume of 615,545. The stock has a market capitalization of $4.02 billion, a P/E ratio of -12.50, a P/E/G ratio of 0.85 and a beta of 0.54. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The company's 50-day simple moving average is $15.77 and its 200-day simple moving average is $17.91. Bausch + Lomb has a twelve month low of $11.21 and a twelve month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.02. The company had revenue of $1.28 billion during the quarter, compared to analysts' expectations of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The business's revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.24 earnings per share. As a group, research analysts predict that Bausch + Lomb will post 0.74 earnings per share for the current year.

Institutional Trading of Bausch + Lomb

Several institutional investors and hedge funds have recently modified their holdings of BLCO. Blue Trust Inc. raised its stake in Bausch + Lomb by 68.3% during the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after acquiring an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Bausch + Lomb during the 4th quarter valued at approximately $72,000. Commonwealth Equity Services LLC acquired a new position in Bausch + Lomb during the 4th quarter worth approximately $181,000. Alpine Global Management LLC bought a new position in Bausch + Lomb in the 4th quarter valued at approximately $181,000. Finally, Covestor Ltd acquired a new stake in Bausch + Lomb in the fourth quarter valued at approximately $188,000. 11.07% of the stock is currently owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.